Tele: 561.316.3330
Breaking Medical Device News

Thursday, October 21, 2021


HomeMBio Diagnostics Inc.Two Contracts for Sepsis Test Development Announces MBio Diagnostics

Two Contracts for Sepsis Test Development Announces MBio Diagnostics

Sepsis tests will be developed in collaboration with the Cincinnati Children’s Hospital Medical Center and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. o address the critical need for more effective sepsis patient management in clinical and field settings

Today MBio Diagnostics, Inc.,announced two new contracts for sepsis test development. The first is a Phase II Small Business Innovative Research grant from the National Institutes of Health (NIH) focused on point-of-care implementation of the pediatric sepsis mortality risk algorithm developed at the Cincinnati Children’s Hospital Medical Center (CCHMC). The second is from The Henry M. Jackson Foundation, Inc. (HJF) for the Advancement of Military Medicine for development of a field-forward 10-plex immunoassay for prediction of sepsis survival in areas where healthcare access is limited.

Sepsis is a devastating cause of morbidity and mortality; estimates of U.S. incidence range from 894,000 to 3.1 million cases annually. Because of its high incidence and high cost of treatment, sepsis imposes a heavy financial burden on the health care system. MBio’s NIH-funded program is in collaboration with Dr. Hector Wong, Director of Critical Care Medicine at CCHMC, whose group has developed a laboratory-based pediatric sepsis prognostic assay. “When managing care for these gravely ill children, we need test results at the bedside in minutes – not hours later in the laboratory,” said Dr. Wong. The CCHMC-MBio test combines five blood-based biomarkers with clinical inputs to quickly stratify patients by mortality risk. Dr. Wong added, “Phase I data on the MBio point-of-care platform showed excellent correlation with data we have been generating in the laboratory over the last several years. We are very excited about the prospect of getting this test into the ICU.”

MBio’s HJF contract is in collaboration with the Austere environments Consortium for Enhanced Sepsis Outcomes (ACESO). The ACESO project is sponsored by the Department of Navy, Naval Medical Research Center. The ACESO group has developed a laboratory-based sepsis management algorithm based on 10 blood biomarkers. The ACESO-MBio project will establish feasibility of quantitative detection of the 10 blood biomarkers on MBio’s simple-to-use, point-of-care device. “The ACESO sepsis tool requires measurement of multiple biomarkers in a single sample very quickly,” said HJF President and CEO Dr. Joseph Caravalho. “The MBio platform seems uniquely positioned to deliver the results we need in a format that can be effectively utilized in challenging field settings encountered in military medicine.”

MBio’s CEO Chris Myatt added, “In addition to the devastating health impacts of sepsis, the financial burden sepsis management places on the healthcare system is enormous. By providing timely results at the point-of-care, the MBio system has the potential to both improve patient outcomes and reduce the overall costs of sepsis management. We are grateful for the confidence the NIH and HJF have shown in our system.”

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company

This infusion of capital will support the initiation of a first-in-human trial of ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men.

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Luciana Borio MD is a respected physician with vast experience in advancing major regulatory and policy agendas for the United States.

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

By using this website you agree to accept Medical Device News Magazine Privacy Policy